Swing Therapeutics, Inc.

Big Health’s flagship insomnia treatment, SleepioRx, is now available by prescription to eligible patients through Swing Care ?? For many people with #fibromyalgia, fatigue and sleeplessness is the symptom that most impacts quality of life. Poor sleep exacerbates pain symptoms, making sleep management a crucial component of care. SleepioRx is a clinically proven, FDA-cleared treatment designed to help patients tackle the root cause of their insomnia and chronic sleep problems. Through a self-paced, app-delivered program, SleepioRx delivers first-line cognitive behavioral therapy (CBT) to help patients better understand their sleep patterns and make lasting changes to their sleep. Starting January 1, 2025, CMS introduced new Medicare reimbursement for digital mental health treatments including SleepioRx. By integrating SleepioRx as a treatment option in Swing Care’s comprehensive approach for fibromyalgia, patients may get access to this leading digital sleep treatment through their insurance. If you or a loved one is enrolled in Medicare and living with fibromyalgia, learn more about Swing Care’s virtual specialty clinic for fibromyalgia at www.swing.care #Fibromyalgia #SleepioRx #HealthTech #ChronicPain #BigHealth #DigitalTherapeutics #HealthcareInnovation See the full announcement: https://lnkd.in/gxjqeZ8Z

Big news at Swing: Evidence from randomized controlled trials of Stanza have been included in the #fibromyalgia treatment guidelines in UpToDate, a leading clinical resource used by healthcare professionals worldwide. ???? Being included in UpToDate represents a significant step in validating Stanza’s role in bringing outcomes-driven, accessible care to both patients and clinicians managing fibromyalgia. Stanza provides evidence-backed digital behavioral therapy that is often unavailable to patients, due to cost, geography, or lack of trained providers. A huge thank you to our dedicated team, researchers, and partners who’ve worked tirelessly to make this kind of care more available to patients. ?? We’re excited for the growing recognition of digital health solutions as valuable tools in managing chronic conditions. Learn more about Stanza at https://lnkd.in/gxNbXZ2v #DigitalTherapy #Fibromyalgia #ChronicPain #UpToDate #HealthcareInnovation #PatientCare #HealthTech #ChronicIllness #DigitalHealth #MedicalGuidelines #FutureOfMedicine

Two years ago Highmark Inc. made a splash by announcing it would cover digital therapeutics cleared by the Food and Drug Administration. In the end, it paid for very few treatments for its members. Now it's trying again. After ironing out some processes, it's announced a medical policy covering three products. And it's actually signed a contract with AppliedVR and has contracts in process with Luminopia and Swing Therapeutics, Inc.. "To give you some idea how much it has moved and changed and we’ve tried to adapt: Most policies in two years have two changes. This one had seven,” Matt Fickie, a senior medical director at Highmark told me. Ultimately, he said: “My goal remains the same: I want to solve niche problems with these.” Read my story: https://lnkd.in/etHY4cTt

Excited to share this positive coverage decision for Stanza, and its ability to expand access for people with #fibromyalgia in Pennsylvania, West Virginia, Delaware, and New York! If you or someone you know has fibromyalgia, you can learn more about Stanza at https://lnkd.in/gxNbXZ2v

Thanks STAT and Mario Aguilar for covering the recent study of Stanza published in The Lancet and how Swing Therapeutics, Inc. is raising the bar for clinical study quality for digital therapies. As we aim for broad adoption for new technologies, establishing the evidence of clinical benefit is essential. https://lnkd.in/giKTkn7X

Thanks to Guilherme Torres Vilarino for the informative commentary on the publication in The Lancet this week: “The results found in the study are essential for professionals who care for patients with fibromyalgia [FM] as they present a new viable treatment alternative. Given the recommendation of multidisciplinary treatment for patients with FM, alternatives that can facilitate access are essential.” We’re honored to bring more awareness to #fibromyalgia with this publication—for providers looking for evidence-based treatments; for researchers looking to increase our collective knowledge about this complex condition; and for patients who are looking to live the life they want. Access the commentary here: https://lnkd.in/gKFMmA6Y Read the full release: https://lnkd.in/gfTCrFCU

Positive phase 3 landmark study of a Digital Therapeutic (DTX)for Fibromyalgia! Published in The Lancet, the PROSPER-FM trial demonstrates that a 12-week, self-guided, smartphone-delivered digital acceptance and commitment therapy (ACT) program is both safe and effective for managing fibromyalgia in adults. Participants in the digital ACT group reported significantly greater improvement in their condition compared to those in the active control group, with 71% of ACT participants showing positive changes versus 22% in the control group. Statistical superiority was observed across nearly all endpoints, including the FIQ-R domains of “function,” “overall impact,” and “symptoms”; pain intensity and pain interference; the PROMIS Fatigue and Sleep Disturbance domains; the Beck Depression Inventory II (BDI II); the Psychological Inflexibility in Pain Scale (PIPS); and the Committed Action Questionnaire (CAQ-8). This opens the way to many new opportunities in non-pharmacologic therapy of fibromyalgia such as : treatment of early fibromyalgia or pre-fibromyalgia in at-risk patients (prevention), treat-to-target strategies, and more... See here the abstract: https://lnkd.in/eNBs3CFD

We’re thrilled to announce the publication in The Lancet of data from the Phase 3 trial of Stanza, a digital therapy for #fibromyalgia symptoms. This research validates Stanza’s clinical benefits for people with fibromyalgia, including improvements in well-being (measured by Patient Global Impression of Change), fibromyalgia severity (measured by the Revised Fibromyalgia Impact Questionnaire (FIQ-R)), and major fibromyalgia symptoms including pain intensity, pain interference, fatigue, sleep disturbance, depression and physical function, when compared to an active control. “Fibromyalgia options are typically limited to a handful of pharmacological interventions that have limited efficacy and that can come with difficult to manage side effects,” said Mike Rosenbluth, CEO of Swing. “This publication validates Stanza as a guideline-directed, non-drug approach that many patients previously couldn’t access, due to few available trained clinicians, geographic limitations, and cost. Read the full release: https://lnkd.in/gfTCrFCU Stanza is now available by prescription through Swing Care, a specialty clinic that offers comprehensive treatment for fibromyalgia. To learn more about Swing Care, visit www.swing.care

Swing has been selected for the 2024 UCSF Rosenman Innovators program, recognizing groundbreaking companies dedicated to advancing healthcare innovation! Read more from CEO Mike Rosenbluth ??